4DX Chart, page-364

First 364 Last

Share
Profile

Follow
hdhtin

635 Posts.

113

04/06/23

13:33

Post #: 68120687
Share

Originally posted by chibba123: ↑

Yes, but if the market only looked at technical progress within the company and used the IPO as it's anchor, then there's no way that the price would have ever gotten down to 30c. I'm super bullish long term, but I also realise that there are many many different games that are played on the stock market. Some are long term buy and holders like you and I. Some trade purely based on chart data.
Off the top of my head, a couple of reasons why it could break down are people freaking out about the US debt ceiling (unlikely but all hell would break loose if they actually defaulted), short term traders seeing the bearish chart signal (and either shorting or just not buying), stubbornly high inflation in the macro economy (meaning some retail holders may exit due to completely unrelated cost of living pressures), and the fact we're coming into June which means anyone who bought in the last month above the current price may wish to crystallise their loss for tax purposes. All have nothing to do with the actual progress of the company.
When playing in this space, I've found that short term traders can actually have quite a significant influence on the price direction (perhaps it's the lack of institutional investors and liquidity), and chart patterns can actually be quite reliable in the short term. It's useful to be able to see things from the perspective of people who are playing a different game to me.

All that being said, it may or may not play out. I just thought it was an interesting observation on the chart which could be worthy of discussion. Whichever way it goes, I'll continue to nibble at it for a long term hold.

Expand

Looks like you've made a losing bet / prediction, mate, with the DOW UP 700+ points and analysts predicting the end of the current bear market.

Based on the above, I will not be surprised to see the SP breach the $1 mark by the end of this week, head and shoulders and other fancy chart data notwithstanding.

30c??
Dream on!

4DX Price at posting: 83.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

There are more pages in this discussion • 470 more messages in this thread...

First 364 Last

Add 4DX (ASX) to my watchlist

(20min delay)
Last 60.5¢		Change 0.005(0.83%)		Mkt cap ! $248.3M

Open	High	Low	Value	Volume
61.0¢	62.0¢	58.0¢	$751.7K	1.240M

Buyers (Bids)

No.	Vol.	Price($)
1	39668	60.5¢

Sellers (Offers)

Price($)	Vol.	No.
62.0¢	14430	1

View Market Depth

No.	Vol.	Price($)
1	39668	0.605
4	16800	0.600
3	42766	0.595
3	29846	0.590
2	30000	0.585

Price($)	Vol.	No.
0.620	14430	1
0.625	7500	1
0.630	66410	2
0.635	32885	4
0.640	23500	3

Last trade - 16.10pm 02/10/2024 (20 minute delay)

4DX (ASX) Chart

4DX Chart, page-364

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

4DX Chart, page-364

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News